Company Overview and News

 
Binani Industries Limited - Extension of Annual General Meeting

2018-08-30 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

 
Binani Industries Limited - Clarification - Financial Results

2018-08-16 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

 
Binani Industries Limited - Financial Result Updates

2018-08-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

1
Ultratech’s resolution plan for Binani Cement submitted at NCLT

2018-06-04 livemint
Kolkata: The resolution professional of Binani Cement Ltd. on Monday submitted the resolution plan of Ultratech Cement Ltd. at the Kolkata bench of the National Company Law Tribunal for its approval even as the tribunal agreed to hear Dalmia Bharat’s objections about Ultratech’s bid.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 500059 ULTRACEMCO

 
Binani Industries Limited - Outcome of Board Meeting

2018-05-31 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

1
Binani lenders okay UltraTech acquisition

2018-05-31 freepressjournal.in
New Delhi : The lenders of Binani Cement have issued letter of intent to UltraTech after approving its bid to acquire the company under the bankruptcy code, Aditya Birla group firm said on Wednesday. The Committee of Creditors (CoC) of Binani Cement on May 28 approved the resolution Plan submitted by UltraTech Cement, it said.
BINANIIND UCLQY UCLQF 532538 500059 ULTRACEMCO

1
Binani Cement lenders back UltraTech’s offer

2018-05-28 livemint
Mumbai: UltraTech Cement Ltd’s Rs7,950 crore bid to acquire Binani Cement Ltd has received near-unanimous backing from lenders to the distressed building material maker even as a legal battle reached the country’s top court, two people aware of the development said.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 PRMQY 500059 500302 ULTRACEMCO PEL

4
Binani Cement lenders vote in favour of UltraTech offer

2018-05-28 moneycontrol
The committee of creditors (CoC) for Binani Cement May 28 voted in favour of accepting UltraTech Cement’s Rs 7,950 crore bid.
BINANIIND 500116 DALMIABHA 533309 UCLQY IDBI UCLQF 532538 500059 ULTRACEMCO SBAZ

1
NCLAT refuses to stay Binani Cement insolvency proceedings

2018-05-22 livemint
New Delhi:The National Company Law Appellate Tribunal (NCLAT) on Tuesday refused to stay the corporate insolvency resolution process for Binani Cement Ltd.
BINANIIND UCLQY UCLQF 532538 500059 ULTRACEMCO

 
Binani Ind offers to repay 100% debt of cement unit

2018-05-17 freepressjournal.in
New Delhi : Binani Industries, which holds a 98.4 per cent stake in debt-ridden Binani Cement, on Wednesday offered to clear the 100 per cent claims of creditors at the National Company Law Appellate Tribunal.
BINANIIND 500059

1
Binani Industries offers to pay 100% debt amount of Binani Cement

2018-05-16 livemint
New Delhi: Binani Industries Ltd, the parent of debt-ridden Binani Cement Ltd, told the National Company Law Appellate Tribunal (NCLAT) on Wednesday that it was ready to pay up all the dues of its subsidiary to its financial and operational creditors in two weeks, if the tribunal so permitted.
BINANIIND DALMIABHA 533309 UCLQY UCLQF 532538 500059 ULTRACEMCO

 
Binani Industries Limited - Shareholders meeting

2018-05-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
BINANIIND 500059

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...